Breast Active Clinical Trials

Numerous clinical trials are always active (ie, open and enrolling patients) in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults who have or are at risk of developing cancer. The buttons below depict the general research categories being investigated in ECOG-ACRIN clinical trials. To access information within a particular category, click on the relevant button. Upon clicking, the color of the button will change from grey to red, and a table will appear on screen. The table will display the study number, study description, lead investigator(s), accrual goal, and the date participating institutions started to open the trial. Please read the ECOG-ACRIN Disclaimer in its entirety before accessing this information.

Need More Information About a Particular Clinical Trial? Contact Us

To view educational materials, click on the links provided in the Educational Materials column. To send an email to the study chair, click on their name and a new email window will open.

Brain

Breast

Cancer Care Delivery Research

Cancer Control and Survivorship

Trials Currently Recruiting Participants - Breast Cancer Committee

STUDY	DESCRIPTION	ECOG-ACRIN STUDY CHAIR (STATISTICIAN)	ACCRUAL GOAL	DATE ACTIVATED	EDUCATIONAL MATERIALS
EA1151/ TMIST	Tomosynthesis Mammographic Imaging Screening Trial (TMIST)	Etta D. Pisano, MD, Chair (Constantine A. Gatsonis, PhD)	165,000	07/06/2017	EA1151 Resources
EA1181/ CompassHER2 pCR	Preoperative THP (taxane, trastuzumab or FDA-approved biosimilar, and pertuzumab) in patients with HER2-positive, stage 2 or 3 breast cancer; postoperative HP (trastuzumab or FDA-approved biosimilar, and pertuzumab) in patients who achieve a pathologic complete response (pCR) to THP, and standard of care therapy in patients who do not achieve pCR) Note: This trial is part of CompassHER2 Trials, a research program testing targeted escalation/de-escalation of therapy in HER2-positive breast cancer. The program is a collaboration between ECOG-ACRIN and the Alliance for Clinical Trials in Oncology.	Nadine Tung, MD, Chair Antonio C. Woff, MD, Co-Chair (Fengmin Zhao, PhD)	450	02/11/2020	EA1181 Resources
EA1183/ FEATURE	FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer (FEATURE)	Jennifer M. Specht, MD, Chair Heather A. Jacene, MD, Co-Chair (Fenghai Duan, PhD)	134	04/02/2020	EA1183 Resources
EAI142	[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer	Farrokh Dehdashti, MD, Co-Chair Hannah M. Linden, MD, Co-Chair Amy Fowler, MD, PhD, Junior Co-Chair Amy Clark, MD, Junior Co-Chair (Zheng Zhang, PhD)	99	02/02/2016	EAI142 Resources
EAZ171	Prospective Validation Trial of Taxane Therapy (Docetaxel or weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neurothapy in African American Women	Bryan P. Schneider, MD, Chair Joseph A. Sparano, MD, Co-Chair (Fengmin Zhao, PhD)	240	06/27/2019	EAZ171 Resources

STUDY DESCRIPTION ECOG-ACRIN STUDY CHAIR
(STATISTICIAN) ACCRUAL
GOAL DATE
ACTIVATED EDUCATIONAL MATERIALS

EA1151/
TMIST
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Etta D. Pisano, MD,
Chair
(Constantine A. Gatsonis, PhD) 165,000 07/06/2017 EA1151 Resources

EA1181/
CompassHER2 pCR Preoperative THP (taxane, trastuzumab or FDA-approved biosimilar, and pertuzumab) in patients with HER2-positive, stage 2 or 3 breast cancer; postoperative HP (trastuzumab or FDA-approved biosimilar, and pertuzumab) in patients who achieve a pathologic complete response (pCR) to THP, and standard of care therapy in patients who do not achieve pCR)

Note: This trial is part of CompassHER2 Trials, a research program testing targeted escalation/de-escalation of therapy in HER2-positive breast cancer. The program is a collaboration between ECOG-ACRIN and the Alliance for Clinical Trials in Oncology. Nadine Tung, MD, Chair
Antonio C. Woff, MD, Co-Chair
(Fengmin Zhao, PhD) 450 02/11/2020 EA1181 Resources

EA1183/
FEATURE FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer (FEATURE) Jennifer M. Specht, MD, Chair
Heather A. Jacene, MD, Co-Chair
(Fenghai Duan, PhD) 134 04/02/2020 EA1183 Resources

EAI142 [18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer Farrokh Dehdashti, MD, Co-Chair
Hannah M. Linden, MD, Co-Chair
Amy Fowler, MD, PhD, Junior Co-Chair
Amy Clark, MD, Junior Co-Chair
(Zheng Zhang, PhD) 99 02/02/2016 EAI142 Resources

EAZ171 Prospective Validation Trial of Taxane Therapy (Docetaxel or weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neurothapy in African American Women Bryan P. Schneider, MD, Chair
Joseph A. Sparano, MD, Co-Chair
(Fengmin Zhao, PhD)
240 06/27/2019 EAZ171 Resources

Download